Clinical trials: COPD Exacerbations
- Condition COPD Exacerbations
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pulmonary Disease, Chronic Obstructive
Exacerbations Among Patients Receiving Breztri (EROS Study)
EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment.
- Conditions
- Pulmonary Disease, Chronic Obstructive, Retrospective Studies
- Trial name
- NCT06514144
- Testing
- BGF
- Where
- United States
- Volunteers
- 2,409 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
EXACOS EG Population
Chronic obstructive pulmonary disease (COPD) is a common, progressive disease characterized by airflow obstruction which is not fully reversible.
- Trial name
- EXACOS EG (NCT06983340)
- Sponsor
- AstraZeneca
Acute Exacerbations of COPD
Development of AECOPD Identification Tool (DETECT Study)
This study is an observational, multi-center and cross sectional study,to develop an identification tool on purpose of differentiating COPD exacerbation from patients with respiratory symptoms in community hospitals of China.
- Trial name
- NCT03556475
- Where
- 7 sites in China
- Volunteers
- 300 people
- Sponsor
- AstraZeneca